Bonesupport Primed For Nasdaq Stockholm Flotation
Executive Summary
Swedish orthobiologics company Bonesupport is seeking to raise SEK500m ($45m) by floating its shares publicly for the first time on the Nasdaq Stockholm stock exchange. Proceeds from the IPO will go towards advancing sales of its existing bone substitute products and conducting a major study to gain US approval of antibiotic-eluting bone filler Cerament G.
You may also be interested in...
Bonesupport Cements Funding With SEK 500m IPO
Swedish orthobiologics company Bonesupport has closed its initial public offering on the Nasdaq Stockholm exchange, raising SEK500m ($57m) from retail and institutional investors.
Bonesupport Banks In More Cash, Pharma Expertise For Bioceramic Bone
Bone substitute materials specialist Bonesupport has strengthened its cash position with an influx of new capital, as well as installed a new chairman to strengthen its pharma know-how as it seeks to grow its drug-eluting bone scaffold business.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.